Key result
Doxazosin at 4 mg/day significantly decreased hand vein vasoconstrictor responses to noradrenaline compared with placebo in normotensive type 1 diabetes patients with microalbuminuria (p=0.006).
Why the study?
Does doxazosin reduce noradrenaline-induced hand vein vasoconstriction and albumin excretion in normotensive type 1 diabetes patients with microalbuminuria?
Population
14 normotensive type 1 diabetes patients with microalbuminuria
Comparison
Doxazosin for six weeks vs Placebo run-in period
Design
Cohort, open
Follow-up
6 weeks of treatment followed by 2-week washout
Authors
Loading...
May support alpha-1 blockade trials in type 1 diabetes microalbuminuria; leaves open effects on albuminuria and outcomes.
Does doxazosin reduce noradrenaline-induced hand vein vasoconstriction and albumin excretion in normotensive type 1 diabetes patients with microalbuminuria?
p-value: p=0.006
Alpha 1-adrenoceptor blockade with doxazosin blunts exaggerated vascular reactivity to noradrenaline in normotensive type 1 diabetes patients with microalbuminuria.
Bodmer et al. (1999) studied Normotensive type 1 diabetes with microalbuminuria (n=14). Doxazosin vs. Placebo was evaluated on Noradrenaline-induced hand vein vasoconstriction (p=0.006). Doxazosin at 4 mg/day significantly decreased hand vein vasoconstrictor responses to noradrenaline compared with placebo in normotensive type 1 diabetes patients with microalbuminuria (p=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: